At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Galantamine +3 moredrug
Likely dose
Galantamine 16 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Racial Differences in Vagal Control of Glucose Homeostasis
In Brief
A Phase 2 clinical trial evaluating Galantamine, Placebo Oral Capsule, and 2 other interventions for Obesity. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsDoris Duke Charitable Foundation
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMar 2015
Primary CompletionOct 2017
TodayJul 2026
First PostedFeb 18, 2015
Enrollment StartMar 1, 2015
Primary CompletionOct 5, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.4 years ago
Interventions
Galantaminedrug
16 mg po prior to the infusion of intralipid
Placebo Oral Capsuledrug
Placebo oral capsule prior to the infusion of intralipid/heparin
Intralipiddrug
Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Heparindrug
heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine